Ken Griffin Erasca, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Erasca, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,100 shares of ERAS stock, worth $26,664. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,100

Previous 3,100 225.81%

Holding current value

$26,664

Previous $7,000 285.71%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.17 - $3.28 $2.22 Million - $3.35 Million	1,022,302 Added 31.04%	4,315,673 $11.8 Million
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $4.4 Million - $6.46 Million	2,456,057 Added 293.33%	3,293,371 $7.77 Million
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $2.19 Million - $3.34 Million	-1,310,280 Reduced 61.01%	837,314 $1.72 Million
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $642,864 - $958,523	384,949 Added 21.84%	2,147,594 $4.57 Million
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $917,651 - $1.36 Million	465,813 Added 35.92%	1,762,645 $3.47 Million
Q2 2023 Aug 14, 2023	SELL	$2.57 - $3.3 $5.23 Million - $6.71 Million	-2,033,736 Reduced 61.06%	1,296,832 $3.58 Million
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $6.77 Million - $11 Million	2,471,895 Added 287.87%	3,330,568 $10 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $2.89 Million - $6.38 Million	744,039 Added 649.06%	858,673 $3.7 Million
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $136,909 - $251,236	23,524 Added 25.82%	114,634 $894,000

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $322M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account